We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current XERS market cap is 521.79M. The company's latest EPS is USD -0.4176 and P/E is -8.33.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Revenue | 48.32M | 44.39M | 40.64M | 48.07M | 54.27M |
| Operating Income | -4.91M | -9.84M | -14.25M | -8.19M | -12.89M |
| Net Income | -12.19M | -13.39M | -18.98M | -15.01M | -15.74M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 49.59M | 110.25M | 163.91M |
| Operating Income | -115.16M | -81.94M | -44.01M |
| Net Income | -122.73M | -94.66M | -62.26M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Assets | 327.78M | 322.6M | 336.62M | 331.73M | 321.1M |
| Total Liabilities | 323.92M | 329.38M | 345.79M | 351.02M | 349.43M |
| Total Equity | 3.87M | -6.78M | -9.18M | -19.29M | -28.32M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 304.36M | 344.52M | 322.6M |
| Total Liabilities | 209.13M | 299.34M | 329.38M |
| Total Equity | 95.23M | 45.19M | -6.78M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Operating | -54.49M | -47.02M | -20.3M | -30.65M | -38.96M |
| Investing | -20.87M | -6M | -19.65M | -15.05M | -5.13M |
| Financing | -379k | -1.61M | 35.19M | 35.85M | 35.77M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Operating | -95.54M | -102.89M | -47.02M |
| Investing | 97.96M | 34.46M | -6M |
| Financing | 27.25M | 127.47M | -1.61M |
| Market Cap | 521.79M |
| Price to Earnings Ratio | -8.33 |
| Price to Sales Ratio | 3.17 |
| Price to Cash Ratio | 7.69 |
| Price to Book Ratio | -76.5 |
| Dividend Yield | - |
| Shares Outstanding | 149.08M |
| Average Volume (1 week) | 1.72M |
| Average Volume (1 Month) | 1.73M |
| 52 Week Change | 69.90% |
| 52 Week High | 3.87 |
| 52 Week Low | 1.69 |
| Spread (Intraday) | 0.32 (9.14%) |
| Company Name | Xeris Biopharma Holdings Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.xerispharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
